Beryl Drugs Intrinsic Value
BERLDRG Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹11.00 | ₹8.80 - ₹13.20 | -34.8% | EPS: ₹0.50, Sector P/E: 22x |
| Book Value Method | asset | ₹40.00 | ₹36.00 - ₹44.00 | +137.1% | Book Value/Share: ₹20.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹33.74 | ₹30.37 - ₹37.11 | +100.0% | Revenue/Share: ₹42.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹33.74 | ₹30.37 - ₹37.11 | +100.0% | EBITDA: ₹2.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹42.18 | ₹33.74 - ₹50.62 | +150.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹5.06 | ₹4.55 - ₹5.57 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹7.83 | ₹7.05 - ₹8.61 | -53.6% | Revenue Growth: 8.8%, Adj P/E: 15.7x |
| Graham Defensive Method | conservative | ₹15.00 | ₹13.50 - ₹16.50 | -11.1% | EPS: ₹0.50, BVPS: ₹20.00 |
Want to compare with current market value? Check BERLDRG share price latest .
Valuation Comparison Chart
BERLDRG Intrinsic Value Analysis
What is the intrinsic value of BERLDRG?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Beryl Drugs (BERLDRG) is ₹33.74 (median value). With the current market price of ₹16.87, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹5.06 to ₹42.18, indicating ₹5.06 - ₹42.18.
Is BERLDRG undervalued or overvalued?
Based on our multi-method analysis, Beryl Drugs (BERLDRG) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 4.50 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.60 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Operating Margin | 4.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.31x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Beryl Drugs
Additional stock information and data for BERLDRG
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |